FIB-4 Index: Definition, Calculation, and Interpretation
What is FIB-4?
The Fibrosis-4 (FIB-4) index is a simple, non-invasive blood-based biomarker that estimates the degree of liver fibrosis using four readily available laboratory values: age, AST, ALT, and platelet count. 1
Originally developed for HCV/HIV coinfection, FIB-4 has become one of the most validated and widely used non-invasive tests for assessing liver fibrosis across multiple chronic liver diseases including HCV, HBV, NAFLD/MASLD, and alcohol-related liver disease 2, 1.
How to Calculate FIB-4
The formula is straightforward and can be calculated at bedside or using free online calculators 1:
FIB-4 = (Age [years] × AST [U/L]) / (Platelet count [10⁹/L] × √ALT [U/L])
All four variables are routinely available in standard clinical practice, making this test cost-free and immediately accessible 1, 3.
Interpretation of Results
Standard Cut-offs for Liver Fibrosis Assessment
FIB-4 uses a two-threshold approach to maximize diagnostic utility 1, 3:
Low Cut-off: FIB-4 < 1.3-1.45
- Purpose: Rule OUT advanced fibrosis (F3-F4)
- Performance: High negative predictive value (>90-95%) 1, 3
- Sensitivity: 74.3% 3
- Clinical meaning: Patients below this threshold are highly unlikely to have advanced fibrosis and typically do not require further invasive testing
The EASL guidelines recommend FIB-4 < 1.3 as the rule-out threshold for NAFLD/ALD 1, while the original validation study used < 1.45 3. Recent meta-analysis data supports < 1.3 for MASLD with pooled sensitivity of 0.73 and specificity of 0.69 4.
High Cut-off: FIB-4 > 3.25
- Purpose: Rule IN advanced fibrosis (F3-F4) or cirrhosis
- Performance: High positive predictive value (82.1%) 3
- Specificity: 98.2% 3
- Clinical meaning: Patients above this threshold have a high probability of advanced fibrosis and should be referred to hepatology for further evaluation
Indeterminate Zone: FIB-4 1.3-3.25
- Approximately one-third of patients fall into this gray zone 1
- These patients require additional testing with either:
- Transient elastography (TE/FibroScan)
- Patented serum tests (ELF™, FibroMeter™, FibroTest®)
- Liver biopsy in select cases 1
Important Caveats and Pitfalls
Age-Related Considerations
FIB-4 performance is affected by age, particularly in patients >65 years 1. Age is a numerator in the formula, so older patients naturally have higher scores even without significant fibrosis.
- Proposed adjusted cut-offs for patients >65 years:
- Rule-out threshold: < 2.0 (instead of 1.3-1.45)
- Rule-in threshold: remains 3.25
- These adjusted thresholds require further external validation 1
Disease-Specific Performance
The diagnostic accuracy varies by underlying liver disease 2:
- Best validated in: HCV, HBV, HIV-HCV coinfection
- Good performance in: NAFLD/MASLD, alcohol-related liver disease
- Modest PPV in NAFLD: FIB-4 more often produces false positives in NAFLD compared to viral hepatitis 1
Factors That Can Falsely Elevate FIB-4
- Thrombocytopenia from any cause (not just portal hypertension) 5
- Acute hepatic inflammation with elevated transaminases
- Medications affecting platelet count (e.g., TNF inhibitors can decrease platelets) 5
- Acute illness states (acute heart failure, sepsis) 6, 7
Non-Hepatic Applications
Recent research shows FIB-4 may reflect systemic vulnerability beyond liver disease 7, 8:
- Predictor of mortality and readmission in frail elderly hospitalized patients 7
- Associated with contrast-induced nephropathy and mortality in acute coronary syndrome 8
- Correlates with diabetic vascular complications 9
Clinical implication: When FIB-4 is elevated in non-hepatic contexts, interpret cautiously and confirm liver fibrosis with imaging (transient elastography) rather than relying on FIB-4 alone 5.
Recommended Clinical Algorithm
For patients with metabolic risk factors and/or alcohol use in primary care 1:
- Calculate FIB-4 from routine labs
- If FIB-4 < 1.3: Advanced fibrosis unlikely, continue routine monitoring
- If FIB-4 > 3.25: Refer to hepatology for advanced fibrosis evaluation
- If FIB-4 1.3-3.25: Perform transient elastography or patented serum test
- If concordant (both elevated or both low): act accordingly
- If discordant: consider liver biopsy
For patients with confirmed chronic liver disease 1:
- Use FIB-4 as initial screening tool
- Combine with imaging (TE preferred) for comprehensive assessment
- Serial monitoring every 1-2 years to detect progression
Comparative Performance
FIB-4 vs. other non-invasive tests 2, 1:
- Similar accuracy to: NAFLD Fibrosis Score (NFS), APRI
- Slightly less accurate than: Patented tests (ELF™, FibroMeter™), transient elastography
- Major advantage: Free, immediately available, no special equipment needed
- Overall diagnostic accuracy: AUROC 0.80-0.85 for advanced fibrosis across studies 2, 1, 3
The 2025 AASLD systematic review found that FIB-4 < 1.45 performs better than APRI < 0.5 for ruling out F2-4 fibrosis, and FIB-4 > 3.25 outperforms APRI > 1.5 for ruling in F3-4 and F4 2.